RetaRick_CA said:

Senior perspective on cardiovascular risk: I'm 66 years old and started this journey skeptically.

Pushing back on RetaRick_CA here. The "earlier than weight loss explains" argument is weaker than this thread makes it sound. Blood pressure and inflammatory markers move fast and are downstream of early weight loss, so the mechanism is not as cleanly separable as the summaries imply.

oliver_london said:

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -1.8 lbs/week average
Fasting glucose (finger stick): stable at 87 mg/dL
Blood pressure (home): 118/73 average
Resting heart rate: 67 bpm (down from 83)
Waist circumference: down 17 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

KevinCompounds said:

The "earlier than weight loss explains" argument is weaker than this thread makes it sound.

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely! My cardiologist is thrilled.

If you're on BP meds and losing weight on a GLP-1, monitor your BP at home regularly. Hypotension symptoms (dizziness, lightheadedness when standing) mean your BP meds may need reduction. Don't wait for your next scheduled appointment — call your doctor.

Following on from sarah.morrison — and this may be the naive question:

How long did you give it before you decided it was working?

julia.endo said:

Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off metoprolol entirely!

SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].

Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.